Patient-Matched Tumor-Normal Sequencing: What It Is and Why It Matters episode artwork

EPISODE · May 28, 2025 · 12 MIN

Patient-Matched Tumor-Normal Sequencing: What It Is and Why It Matters

from OncTimes Talk

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

Episode metadata supplied by the publisher feed · Published May 28, 2025

Embed this episode

NOW PLAYING

Patient-Matched Tumor-Normal Sequencing: What It Is and Why It Matters

0:00 12:34

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncTimes Talk?

This episode is 12 minutes long.

When was this OncTimes Talk episode published?

This episode was published on May 28, 2025.

Can I download this OncTimes Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!